PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Mobocertinib→

Mobocertinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1847461-43-1
Molecular formula
C32H39N7O4
Molecular weight
585.71 g/mol
Drug class
Irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorhistorical antineoplastic small molecule
Mechanism of action
Irreversibly inhibits EGFR kinase, including mutant EGFR exon 20 insertion variants, reducing downstream oncogenic signalling. The drug had an accelerated US approval for EGFR exon 20 insertion-mutated NSCLC, but that indication was withdrawn in July 2024 after confirmatory evidence did not verify clinical benefit.
Indications / reported uses
  • Historical US indication: treatment of adults with locally advanced or metastatic EGFR exon 20 insertion-mutated non-small-cell lung cancer (NSCLC) whose disease had progressed on or after platinum-based chemotherapy. The US approval was withdrawn 15 July 2024; do not present this as a current US-authorised treatment.

Sources: US FDA — Withdrawn cancer accelerated approvals · Federal Register — Withdrawal of EXKIVITY approval, 15 July 2024 · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Mobocertinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mobocertinib Permitted Daily Exposure (PDE) report (the Mobocertinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mobocertinib Occupational Exposure Limit (OEL) report (the Mobocertinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.